Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TLR7 | Q9NYK1 | 18/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
| ▸ | GBA1 | P04062 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6414152 | 0.85 | SMN1; SMN2 (0.36) | TLR7SMN1; SMN2 | |
| SCHEMBL3093082 | 0.85 | GNRHR (0.39) | TLR7 | |
| SCHEMBL4329235 | 0.84 | TLR7 (0.42) | TLR7SMN1; SMN2GBA1 | |
| SCHEMBL1948125 | 0.81 | CNR2 (0.39) | TLR7 | |
| SCHEMBL1952878 | 0.80 | CNR2 (0.44) | TLR7 | |
| SCHEMBL4331154 | 0.80 | TLR7 (0.56) | TLR7 | |
| SCHEMBL1951717 | 0.79 | PIM1 (0.44) | TLR7 | |
| SCHEMBL4333747 | 0.76 | TLR7 (0.46) | TLR7 | |
| SCHEMBL5106169 | 0.75 | TLR7 (0.40) | TLR7GBA1 | |
| SCHEMBL20796986 | 0.73 | SMN1; SMN2 (0.37) | TLR7SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 38 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7612083-B2 | Urea substituted imidazoquinoline ethers | COLEY PHARMACEUTICAL GROUP, INC. (US) | 2009-11-03 | — | — | US | disclosed |
| US-20080306252-A1 | SULFONAMIDO ETHER SUBSTITUTED IMIDAZOQUINOLINES | COLEY PHARMACEUTICAL GROUP, INC. (US) | 2008-12-11 | — | — | US | disclosed |
| US-7214675-B2 | Urea substituted imidazoquinoline ethers | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2007-05-08 | — | — | US | disclosed |
| EP-1341790-B1 | SULFONAMIDO ETHER SUBSTITUTED IMIDAZOQUINOLINES | 3M INNOVATIVE PROPERTIES CO (US) | 2007-02-14 | — | — | EP | disclosed |
| US-7132429-B2 | Sulfonamido ether substituted imidazoquinolines | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2006-11-07 | — | — | US | disclosed |
| US-7115622-B2 | Amido ether substituted imidazoquinolines | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2006-10-03 | — | — | US | disclosed |
| US-7078523-B2 | Urea substituted imidazoquinoline ethers | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2006-07-18 | — | — | US | disclosed |
| US-7049439-B2 | Immunomodulators for inducing cytokine biosynthesis; viricides; antitumor agents | 3M INNOVATIVE PROPERTIES CO. (US) | 2006-05-23 | — | — | US | disclosed |
| EP-1343784-B1 | UREA SUBSTITUTED IMIDAZOQUINOLINE ETHERS and pharmaceutical compositions comprising the same. | 3M INNOVATIVE PROPERTIES CO (US) | 2006-03-08 | — | — | EP | disclosed |
| US-20050234088-A1 | Urea substituted imidazoquinoline ethers | 3M INNOVATIVE PROPERTIES COMPANY | 2005-10-20 | — | — | US | disclosed |
| EP-1341792-A2 | AMIDO ETHER SUBSTITUTED IMIDAZOQUINOLINES | 3M Innovative Properties Company (US) | 2003-09-10 | — | — | EP | disclosed |
| EP-1341790-A2 | SULFONAMIDO ETHER SUBSTITUTED IMIDAZOQUINOLINES | 3M Innovative Properties Company (US) | 2003-09-10 | — | — | EP | disclosed |
| US-20030158192-A1 | Urea substituted imidazoquinoline ethers | 3M INNOVATIVE PROPERTIES COMPANY | 2003-08-21 | — | — | US | disclosed |
| US-20030139441-A1 | Sulfonamido ether substituted imidazoquinolines | UBS AG, STAMFORD BRANCH | 2003-07-24 | — | — | US | disclosed |
| US-20030130518-A1 | Urea substituted imidazoquinoline ethers | COLEY PHARMACEUTICAL GROUP, INC. | 2003-07-10 | — | — | US | disclosed |
| US-20030096835-A1 | Amido ether substituted imidazoquinolines | 3M INNOVATIVE PROPERTIES COMPANY | 2003-05-22 | — | — | US | disclosed |
| US-20020193396-A1 | Sulfonamido ether substituted imidazoquinolines | 3M INNOVATIVE PROPERTIES COMPANY | 2002-12-19 | — | — | US | disclosed |
| WO-2002046191-A2 | UREA SUBSTITUTED IMIDAZOQUINOLINE ETHERS | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2002-06-13 | — | — | WO | disclosed |
| WO-2002046190-A2 | SULFONAMIDO ETHER SUBSTITUTED IMIDAZOQUINOLINES | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2002-06-13 | — | — | WO | disclosed |
| WO-2002046188-A2 | AMIDO ETHER SUBSTITUTED IMIDAZOQUINOLINES | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2002-06-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080306252-A1 | SULFONAMIDO ETHER SUBSTITUTED IMIDAZOQUINOLINES | IFNG, IRF3, IL2 | TLR7 24/4885SMN1; SMN2 2320/4885GBA1 684/4885 |
| US-20030158192-A1 | Urea substituted imidazoquinoline ethers | IRF3, EIF2AK2, IFNG | TLR7 84/4885SMN1; SMN2 3884/4885GBA1 2308/4885 |
| US-20030139441-A1 | Sulfonamido ether substituted imidazoquinolines | IFNG, IRF3, IL2 | TLR7 24/4885SMN1; SMN2 2320/4885GBA1 684/4885 |
| US-20050234088-A1 | Urea substituted imidazoquinoline ethers | IRF3, EIF2AK2, IFNG | TLR7 74/4885SMN1; SMN2 3791/4885GBA1 2310/4885 |
| US-20030130518-A1 | Urea substituted imidazoquinoline ethers | IRF3, EIF2AK2, IFNG | TLR7 84/4885SMN1; SMN2 3884/4885GBA1 2308/4885 |
| US-20030096835-A1 | Amido ether substituted imidazoquinolines | IFNG, IRF3, EIF2AK2 | TLR7 14/4885SMN1; SMN2 3812/4885GBA1 2508/4885 |
| US-20020193396-A1 | Sulfonamido ether substituted imidazoquinolines | IFNG, IRF3, IL2 | TLR7 24/4885SMN1; SMN2 2320/4885GBA1 684/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.